Jacob Johnson
Stock Analyst at Stephens & Co.
(3.09)
# 1,408
Out of 4,479 analysts
68
Total ratings
42.86%
Success rate
1.7%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TKNO Alpha Teknova | Reiterates: Overweight | $15 | $1.21 | +1,139.67% | 4 | May 14, 2024 | |
| MASS 908 Devices | Reiterates: Overweight | $14 | $4.77 | +193.50% | 3 | May 13, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $3.83 | +187.21% | 5 | Apr 23, 2024 | |
| CTLT Catalent | Reiterates: Equal-Weight | $64 | $56.16 | +13.07% | 4 | Apr 4, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $18.73 | +102.88% | 2 | Mar 25, 2024 | |
| CYRX Cryoport | Reiterates: Equal-Weight | $17 | $6.39 | +166.04% | 3 | Mar 13, 2024 | |
| CDMO Avid Bioservices | Maintains: Overweight | $15 → $12 | $7.12 | +68.54% | 5 | Mar 11, 2024 | |
| CERS Cerus | Reiterates: Equal-Weight | $2.5 | $1.72 | +45.35% | 2 | Mar 7, 2024 | |
| STE STERIS | Reiterates: Overweight | $250 | $218.54 | +14.40% | 4 | Feb 9, 2024 | |
| AZTA Azenta | Reiterates: Equal-Weight | $70 | $51.04 | +37.15% | 4 | Feb 8, 2024 | |
| TECH Bio-Techne | Maintains: Overweight | $92 → $87 | $71.61 | +21.49% | 7 | Feb 2, 2024 | |
| WST West Pharmaceutical Services | Maintains: Overweight | $420 → $390 | $324.55 | +20.17% | 8 | Oct 27, 2023 | |
| LFCR Lifecore Biomedical | Maintains: Equal-Weight | $8 → $9 | $4.72 | +90.68% | 3 | Sep 1, 2023 | |
| NEO NeoGenomics | Upgrades: Overweight | $16 → $18 | $13.93 | +29.22% | 4 | Aug 21, 2023 | |
| RGEN Repligen | Maintains: Overweight | $180 → $200 | $123.32 | +62.18% | 3 | Aug 3, 2023 | |
| CDXS Codexis | Reiterates: Overweight | $6 | $2.99 | +100.67% | 2 | Jul 21, 2023 | |
| BLFS BioLife Solutions | Maintains: Overweight | $27 → $29 | $20.79 | +39.49% | 3 | Jul 17, 2023 | |
| LGND Ligand Pharmaceuticals | Maintains: Overweight | $153 → $130 | $84.85 | +53.21% | 1 | May 16, 2022 | |
| CRL Charles River Laboratories International | Initiates: Overweight | $377 | $203.24 | +85.49% | 1 | Apr 7, 2022 |
Alpha Teknova
May 14, 2024
Reiterates: Overweight
Price Target: $15
Current: $1.21
Upside: +1,139.67%
908 Devices
May 13, 2024
Reiterates: Overweight
Price Target: $14
Current: $4.77
Upside: +193.50%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $3.83
Upside: +187.21%
Catalent
Apr 4, 2024
Reiterates: Equal-Weight
Price Target: $64
Current: $56.16
Upside: +13.07%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $18.73
Upside: +102.88%
Cryoport
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $6.39
Upside: +166.04%
Avid Bioservices
Mar 11, 2024
Maintains: Overweight
Price Target: $15 → $12
Current: $7.12
Upside: +68.54%
Cerus
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.72
Upside: +45.35%
STERIS
Feb 9, 2024
Reiterates: Overweight
Price Target: $250
Current: $218.54
Upside: +14.40%
Azenta
Feb 8, 2024
Reiterates: Equal-Weight
Price Target: $70
Current: $51.04
Upside: +37.15%
Bio-Techne
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $71.61
Upside: +21.49%
West Pharmaceutical Services
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $324.55
Upside: +20.17%
Lifecore Biomedical
Sep 1, 2023
Maintains: Equal-Weight
Price Target: $8 → $9
Current: $4.72
Upside: +90.68%
NeoGenomics
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $13.93
Upside: +29.22%
Repligen
Aug 3, 2023
Maintains: Overweight
Price Target: $180 → $200
Current: $123.32
Upside: +62.18%
Codexis
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.99
Upside: +100.67%
BioLife Solutions
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $20.79
Upside: +39.49%
Ligand Pharmaceuticals
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $84.85
Upside: +53.21%
Charles River Laboratories International
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $203.24
Upside: +85.49%